Millennium Management’s NeuBase Therapeutics NBSE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-1,115
Closed -$9K – 7225
2022
Q3
$9K Buy
+1,115
New +$18.4K ﹤0.01% 6692
2022
Q2
– Sell
-869
Closed -$33K – 7675
2022
Q1
$33K Sell
869
-494
-36% -$17.1K ﹤0.01% 6519
2021
Q4
$77K Sell
1,363
-47
-3% -$3.16K ﹤0.01% 6358
2021
Q3
$102K Sell
1,410
-7,291
-84% -$558K ﹤0.01% 6430
2021
Q2
$834K Buy
8,701
+6,388
+276% +$706K ﹤0.01% 4835
2021
Q1
$342K Buy
2,313
+1,328
+135% +$241K ﹤0.01% 5121
2020
Q4
$138K Buy
+985
New +$160K ﹤0.01% 4962
2020
Q3
– Sell
-20,966
Closed -$3.68M – 4914
2020
Q2
$3.68M Buy
20,966
+19,794
+1,689% +$3.31M 0.01% 2041
2020
Q1
$167K Sell
1,172
-261
-18% -$34.5K ﹤0.01% 3444
2019
Q4
$206K Buy
+1,433
New +$168K ﹤0.01% 3865
2017
Q3
– Sell
-44
Closed -$11K – 3956
2017
Q2
$11K Buy
+44
New +$11.8K ﹤0.01% 3395
2016
Q2
– Sell
-25
Closed -$33K – 3684
2016
Q1
$33K Buy
+25
New +$35.6K ﹤0.01% 3172
2015
Q4
– Sell
-60
Closed -$66K – 3846
2015
Q3
$66K Sell
60
-204
-77% -$236K ﹤0.01% 3316
2015
Q2
$265K Sell
264
-3
-1% -$3.24K ﹤0.01% 2938
2015
Q1
$272K Sell
267
-1,802
-87% -$5.95M ﹤0.01% 3099
2014
Q4
$6.9M Sell
2,069
-143
-6% -$438K 0.01% 1195
2014
Q3
$6.41M Sell
2,212
-408
-16% -$1.35M 0.02% 1137
2014
Q2
$10M Buy
2,620
+370
+16% +$1.39M 0.03% 828
2014
Q1
$12.2M Buy
+2,250
New +$11.8M 0.04% 682

Other funds holding NBSE

Millennium Management's NBSE Position: Q4 2022 in Review

Millennium Management sold out of NeuBase Therapeutics (NBSE) in Q4 2022, closing a stake of 1,115 shares — an estimated $9K sold.

Millennium Management first reported a position in NBSE in Q1 2014 and held it in 19 quarters. The position peaked at $12.2M in Q1 2014. 34 funds tracked by Wall St. Rank hold NBSE as of Q4 2022.

  • Millennium Management reported no remaining NeuBase Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Millennium Management sold 1,115 NeuBase Therapeutics shares in Q4 2022, an estimated $9K.
  • Millennium Management first reported a position in NeuBase Therapeutics in Q1 2014 and held it in 19 quarters.
  • Millennium Management's NeuBase Therapeutics position peaked at $12.2M in Q1 2014.
  • 34 funds tracked by Wall St. Rank held NeuBase Therapeutics as of Q4 2022.

Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.